Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (3): 302-307.doi: 10.3969/j.issn.1000-6621.2019.03.011
• Original Articles • Previous Articles Next Articles
Xia YU1,Jing-jing LUO1,Li-ping ZHAO1,Yang XU2,Qian LIANG1,Yi-feng MA1,Ling-ling DONG1,Hai-rong HUANG1()
Received:
2018-09-20
Online:
2019-03-10
Published:
2019-03-15
Contact:
Hai-rong HUANG
E-mail:huanghairong@tb123.org
Xia YU,Jing-jing LUO,Li-ping ZHAO,Yang XU,Qian LIANG,Yi-feng MA,Ling-ling DONG,Hai-rong HUANG. In vitro activity of meropenem against non-tuberculous Mycobacteria[J]. Chinese Journal of Antituberculosis, 2019, 41(3): 302-307. doi: 10.3969/j.issn.1000-6621.2019.03.011
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.03.011
标准菌株号 | 拉丁文名称 | 中文名称 | MIC(μg/ml) | |
---|---|---|---|---|
RGM 菌种 | ||||
ATCC 19977 | Mycobacterium abscessus | 脓肿分枝杆菌 | 64 | |
ATCC 27406 | Mycobacterium agri | 田野分枝杆菌 | 16 | |
ATCC 27280 | Mycobacterium aichiense | 爱知分枝杆菌 | 0.25 | |
ATCC 23366 | Mycobacterium aurum | 金色分枝杆菌 | 2 | |
ATCC 33464 | Mycobacterium austroafricanum | 南非分枝杆菌 | >64 | |
ATCC 14472 | Mycobacterium chelonae | 龟分枝杆菌 | >64 | |
ATCC 19627 | Mycobacterium chitae | 千田分枝杆菌 | 0.5 | |
ATCC 27278 | Mycobacterium chubuense | 楚布分枝杆菌 | 8 | |
DSM 44829 | Mycobacterium cosmeticum | 美容品分枝杆菌 | 2 | |
ATCC 19340 | Mycobacterium diernhoferi | 迪氏分枝杆菌 | 0.5 | |
ATCC 35219 | Mycobacterium fallax | 诡诈分枝杆菌 | >64 | |
ATCC 6841 | Mycobacterium fortuitum | 偶发分枝杆菌 | 4 | |
ATCC 27726 | Mycobacterium gadium | 加地斯分枝杆菌 | 0.25 | |
ATCC 43909 | Mycobacterium gilvum | 浅黄分枝杆菌 | 4 | |
ATCC BAA-955 | Mycobacterium goodii | 古德分枝杆菌 | 4 | |
DSM 44124 | Mycobacterium mucogenicum | 产黏液分枝杆菌 | 1 | |
ATCC 25795 | Mycobacterium neoaurum | 新金色分枝杆菌 | 1 | |
ATCC 27023 | Mycobacterium obuense | 奥布分枝杆菌 | 32 | |
ATCC 19686 | Mycobacterium parafortuitum | 副偶发分枝杆菌 | 8 | |
DSM 43271 | Mycobacterium peregrinum | 外来分枝杆菌 | 0.25 | |
ATCC 11758 | Mycobacterium phlei | 草分枝杆菌 | 32 | |
ATCC 33776 | Mycobacterium porcinum | 猪分枝杆菌 | 2 | |
ATCC 35154 | Mycobacterium pulveris | 灰尘分枝杆菌 | 0.25 | |
ATCC 35796 | Mycobacterium senegalense | 塞内加尔分枝杆菌 | 8 | |
ATCC 700731 | Mycobacterium septicum | 败血症分枝杆菌 | 0.25 | |
ATCC 25275 | Mycobacterium simiae | 猿分枝杆菌 | 0.25 | |
ATCC 19420 | Mycobacterium smegmatis | 耻垢分枝杆菌 | 2 | |
ATCC 19527 | Mycobacterium thermoresistibile | 抗热分枝杆菌 | 4 | |
ATCC 27282 | Mycobacterium tokaiense | 东海分枝杆菌 | 1 | |
ATCC 15483 | Mycobacterium vaccae | 母牛分枝杆菌 | 16 | |
标准菌株号 | 拉丁文名称 | 中文名称 | MIC(μg/ml) | |
SGM 菌种 | ||||
ATCC 25276 | Mycobacterium asiaticum | 亚洲分枝杆菌 | 8 | |
ATCC 25291 | Mycobacterium avium | 鸟分枝杆菌 | 64 | |
DSM 44243 | Mycobacterium celatum | 隐蔽分枝杆菌 | 16 | |
ATCC 15754 | Mycobacterium gastri | 胃分枝杆菌 | 0.5 | |
ATCC 14470 | Mycobacterium gordonae | 戈登分枝杆菌 | 0.25 | |
ATCC 13950 | Mycobacterium intracellulare | 胞内分枝杆菌 | 64 | |
ATCC 12478 | Mycobacterium kansasii | 堪萨斯分枝杆菌 | 64 | |
ATCC 19422 | Mycobacterium microti | 田鼠分枝杆菌 | 2 | |
ATCC 19530 | Mycobacterium nonchromogenicum | 不产色分枝杆菌 | 1 | |
DSM 44648 | Mycobacterium parascrofulaceum | 副偶发分枝杆菌 | 32 | |
ATCC 19981 | Mycobacterium scrofulaceum | 瘰疬分枝杆菌 | 64 | |
ATCC 35799 | Mycobacterium szulgai | 苏尔加分枝杆菌 | 0.5 | |
ATCC 15755 | Mycobacterium terrae | 土分枝杆菌 | 64 | |
ATCC 23292 | Mycobacterium triviale | 次要分枝杆菌 | >64 | |
ATCC 27294 | Mycobacterium tuberculosis (H37Rv) | 结核分枝杆菌 | 2 | |
ATCC 19250 | Mycobacterium xenopi | 蟾分枝杆菌 | 64 |
分类 | 拉丁名称 | 中文名称 | 菌株数量 | MIC (μg/ml) |
---|---|---|---|---|
SGM | Mycobacterium arupense | 阿普罗分枝杆菌 | 4 | 0.5(1),16(1),>64(2) |
Mycobacterium xenopi | 蟾分枝杆菌 | 4 | 32(4) | |
Mycobacterium szulgai | 苏尔加分枝杆菌 | 3 | 16(2),32(1) | |
Mycobacterium parascrofulaceum | 副瘰疬分枝杆菌 | 1 | 16(1) | |
Mycobacterium terrae | 土分枝杆菌 | 1 | >64(1) | |
Mycobacterium malmoense | 玛尔摩分枝杆菌 | 1 | 8(1) | |
RGM | Mycobacterium chelonae | 龟分枝杆菌 | 3 | 0.25(1),4(1),>64(1) |
Mycobacterium holsaticum | 荷尔斯泰因分枝杆菌 | 1 | >64 | |
Mycobacterium massiliense | 马赛分枝杆菌 | 3 | >64(3) |
[1] |
Falkinham JO, 3rd . Ecology of nontuberculous mycobacteria-where do human infections come from? Semin Respir Crit Care Med, 2013,34(1):95-102.
doi: 10.1055/s-00000075 URL |
[2] |
Yu X, Liu P, Liu G , et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis. J Infect, 2016,73(6):558-567.
doi: 10.1016/j.jinf.2016.08.020 URL pmid: 27717784 |
[3] |
Lin C, Russell C, Soll B , et al. Increasing prevalence of nontuberculous mycobacteria in respiratory specimens from US-Affiliated Pacific Island Jurisdictions. Emerg Infect Dis, 2018,24(3):485-491.
doi: 10.3201/eid2403.171301 URL |
[4] | de Mello KG, Mello FC, Borga L , et al. Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993—2011. Emerg Infect Dis, 2013,19(3):393-399. |
[5] |
Li G, Pang H, Guo Q , et al. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria. Int J Antimicrob Agents, 2017,49(3):364-374.
doi: 10.1016/j.ijantimicag.2016.10.024 URL pmid: 28131606 |
[6] | Clinical and Laboratory Standards Institute. Clinical and Laboratory Standards Institute Document M24-A2Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard. second ed. Wayne, PA: CLSI, 2011. |
[7] |
Luo J, Yu X, Jiang G , et al. In vitro activity of clofazimine against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob agents chemother, 2018,62(7):e00072-18.
doi: 10.1128/AAC.00072-18 URL pmid: 29760127 |
[8] |
Coban AY, Bilgin K, Tasdelen Fisgin N , et al. Effect of mero-penem against multidrug-resistant Mycobacterium tuberculosis. J chemother, 2008,20(3):395-396.
doi: 10.1179/joc.2008.20.3.395 URL pmid: 1860660232 |
[9] |
England K, Boshoff HI, Arora K , et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrobial Agents Chemother, 2012,56(6):3384-3387.
doi: 10.1128/AAC.05690-11 URL |
[10] |
Horita Y, Maeda S, Kazumi Y , et al. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with beta-lactamase inhibitors. Antimicrob Agents Chemother, 2014,58(11):7010-7014.
doi: 10.1128/AAC.03539-14 URL pmid: 25224000 |
[11] |
中华医学会结核病学分会, 分枝杆菌菌种中文译名原则专家共识编写组. 分枝杆菌菌种中文译名原则专家共识. 中华结核和呼吸杂志, 2018,41(7):522-528.
doi: 10.3760/cma.j.issn.1001-0939.2018.07.003 URL |
[12] |
Pang Y, Zheng H, Tan Y , et al. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother, 2017,61(5):e02627-16.
doi: 10.1128/AAC.02627-16 URL pmid: 28242674 |
[13] |
Santin M, Barrabeig I, Malchair P , et al. Pulmonary infections with nontuberculous mycobacteria, Catalonia, Spain, 1994-2014. Emerg Infect Dis, 2018,24(6):1091-1094.
doi: 10.3201/eid2406.172095 URL pmid: 29774836 |
[14] |
Brode SK, Marchand-Austin A, Jamieson FB , et al. Pulmonary versus nonpulmonary nontuberculous mycobacteria, Ontario, Canada. Emerg Infect Dis, 2017,23(11):1898-1901.
doi: 10.3201/eid2311.170959 URL pmid: 29048292 |
[15] |
Zhang D, Wang Y, Lu J , et al. In vitro activity of β-lactams in combination with β-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother, 2016,60(1):393-399.
doi: 10.1128/AAC.01035-15 URL |
[16] |
Brown-Elliott BA, Killingley J, Vasireddy S , et al. In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing mycobacteria and nocardia by use of broth microdilution and etest. J Clin Microbiol, 2016,54(6):1586-1592.
doi: 10.1128/JCM.00298-16 URL |
[17] |
Bulik CC, Christensen H, Li P , et al. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother, 2010,54(2):804-810.
doi: 10.1128/AAC.01190-09 URL pmid: 19995927 |
[1] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[2] | MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925. |
[3] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[4] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[5] | LIANG Rui-yun, FANG Wei-jun, REN Hui-li, LI Hui-ru, ZHANG Hui. Study on CT manifestations of non-tuberculous mycobacterium pulmonary disease patients with and without diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 962-967. |
[6] | Beijing Chest Hospital, Capital Medical University, Non-tuberculous Mycobacterial Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on off-label use of drugs for non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 769-787. |
[7] | CHEN Ning, SUN Lin, SHEN A-dong, HE Qiu-shui. Possible causes of infection after BCG vaccination [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 869-873. |
[8] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[9] | LI Xiao-kun, YUAN Yan-li, YANG Guang-xu, WU Yuan-yuan. Design and application of Tuberculosis Designated Hospital Information Management Platform in Changchun [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 671-675. |
[10] | LIU Guang-tian, LIU Tao, WANG Xiao-wei, LEI Juan, TIAN Xiao-mei, WANG Xiao-lin. Application of “Internet+Medical Treatment” model in tuberculosis prevention and treatment in Ningxia [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 676-681. |
[11] | WANG Ni, ZHANG Hui, ZHANG Tie-juan, CHEN Bin, LEI Juan, SUN Miao-miao, HUANG Fei. Analysis of using electronic pillbox to assist the medication management of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 682-686. |
[12] | SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717. |
[13] | BAO Xun-di, JIANG Yue, LIANG Suo, CHENG Hong-yan, XIA Guang-xiu, WANG Chao, YE Qian, WANG Shu, WANG Qing. Analysis of the clinical isolation rate, population distribution and drug resistance of non-tuberculous mycobacteria in Anhui [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 718-724. |
[14] | MA Jin-bao, REN Fei, ZENG Ling-cheng, CHEN Ming-wei. Analysis of drug susceptibility of 680 patients with multidrug-resistant tuberculosis in Xi’an City from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 609-613. |
[15] | QIN Zhong-hua, JING Ye, DU Yan-qing, SONG Xiao-mei, ZHANG Li-xia. Spectrum and drug resistance analysis of 339 strains of nontuberculous mycobacterium isolated from clinical practice [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 630-633. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||